MedTrace Logo

Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine

NCT03193359 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-07-14

No results posted yet for this study

Summary

This study is an open-label extension study to evaluate the safety, tolerability and efficacy of BOTOX® as headache prophylaxis in Chinese patients with chronic migraine who have successfully completed the double-blind study: 1313-301-008.

Conditions

  • Migraine Disorders

Interventions

BIOLOGICAL

botulinum toxin Type A

Botulinum toxin Type A (BOTOX®) IM 155U to 195U injections in head/neck areas.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Arlene Lum · Allergan

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2021-09-09
Completion
2021-09-09

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193359 on ClinicalTrials.gov